Description
The authors call for biomarker-guided clinical trials but don’t identify specific biomarkers for IF monitoring in neurodegeneration. This knowledge gap prevents safe, personalized implementation in at-risk populations.
Gap type: open_question Source paper: Intermittent Fasting as a Neuroprotective Strategy: Gut-Brain Axis Modulation and Metabolic Reprogramming in Neurodegenerative Disorders. (2025, Nutrients, PMID:40732891)